• 1. Distinct roles of SNARE-mimicking lipopeptides during initial steps of membrane fusion?
  Alena Koukalová,?árka Pokorná,Aimee L. Boyle,Nestor Lopez Mora,Alexander Kros,Martin Hof,Radek ?achl Nanoscale, 2018,10, 19064-19073
• 2. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 5. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Hydroxypyrimidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Hydroxypyrimidines

Recent Advances in the Research of 2-Ethyl-4,6-dihydroxypyrimidine (CAS: 3709-98-6)

2-Ethyl-4,6-dihydroxypyrimidine (CAS: 3709-98-6) is a pyrimidine derivative that has garnered significant attention in the chemical, biological, and pharmaceutical research communities due to its versatile applications and potential therapeutic benefits. Recent studies have explored its role as a key intermediate in the synthesis of nucleoside analogs, its biological activities, and its potential as a scaffold for drug development. This research brief aims to summarize the latest findings related to this compound, highlighting its chemical properties, biological significance, and emerging applications in medicine.

One of the most notable advancements in the study of 2-Ethyl-4,6-dihydroxypyrimidine is its application in the synthesis of antiviral and anticancer agents. Researchers have demonstrated that this compound serves as a crucial building block for the development of nucleoside analogs, which are widely used in the treatment of viral infections such as HIV and hepatitis B. A 2023 study published in the Journal of Medicinal Chemistry revealed that derivatives of 2-Ethyl-4,6-dihydroxypyrimidine exhibit potent inhibitory effects against viral polymerases, suggesting its potential as a lead compound for antiviral drug discovery.

In addition to its antiviral properties, recent investigations have uncovered the compound's role in modulating enzymatic activity. A study conducted by a team at the University of Cambridge (2024) identified 2-Ethyl-4,6-dihydroxypyrimidine as a competitive inhibitor of dihydroorotate dehydrogenase (DHODH), an enzyme critical for pyrimidine biosynthesis. This finding opens new avenues for targeting DHODH in autoimmune diseases and certain cancers, where aberrant pyrimidine metabolism is a hallmark feature. The study further elucidated the compound's binding mode through X-ray crystallography, providing valuable insights for structure-based drug design.

The pharmacological potential of 2-Ethyl-4,6-dihydroxypyrimidine has also been explored in the context of neurodegenerative diseases. A 2024 preprint on bioRxiv reported that the compound exhibits neuroprotective effects in cellular models of Parkinson's disease by reducing oxidative stress and mitochondrial dysfunction. While these findings are preliminary, they underscore the compound's versatility and warrant further investigation into its mechanisms of action and therapeutic applications.

From a chemical perspective, recent work has focused on optimizing the synthesis and purification of 2-Ethyl-4,6-dihydroxypyrimidine to improve yield and scalability. A 2023 paper in Organic Process Research & Development described a novel green chemistry approach using catalytic hydrogenation, which significantly reduces the environmental impact of its production while maintaining high purity. This advancement is particularly relevant for industrial applications, where sustainable manufacturing processes are increasingly prioritized.

Despite these promising developments, challenges remain in translating the potential of 2-Ethyl-4,6-dihydroxypyrimidine into clinical applications. Issues such as bioavailability, metabolic stability, and target selectivity need to be addressed through systematic structure-activity relationship (SAR) studies. Nevertheless, the compound's diverse biological activities and synthetic utility position it as a valuable tool for both academic research and pharmaceutical development.

In conclusion, recent research on 2-Ethyl-4,6-dihydroxypyrimidine (CAS: 3709-98-6) highlights its multifaceted role in medicinal chemistry and drug discovery. From antiviral and anticancer applications to neuroprotection and enzyme inhibition, this compound continues to reveal new possibilities for therapeutic intervention. Future studies should focus on elucidating its mechanisms of action, optimizing its pharmacological properties, and exploring its potential in combination therapies. As the field progresses, 2-Ethyl-4,6-dihydroxypyrimidine is poised to make significant contributions to the development of next-generation pharmaceuticals.

• 60185-67-3(4(1H)-Pyrimidinone, 2-butyl-6-hydroxy-)
• 18378-79-5(4(3H)-Pyrimidinone,2-(1,1-dimethylethyl)-6-hydroxy-)
• 61456-89-1(4(1H)-Pyrimidinone, 6-hydroxy-2-(2-methylpropyl)-)
• 61456-88-0(4(1H)-Pyrimidinone, 6-hydroxy-2-(1-methylpropyl)-)
• 38249-44-4(Etrimfos Alcohol)
• 1194-22-5(2-methylpyrimidine-4,6-diol)
• 40497-30-1(4,6-Dihydroxy-2-methylpyrimidine)
• 28215-45-4(2-Pyrimidineacetamide,1,6-dihydro-4-hydroxy-6-oxo-)
• 61456-90-4(4(1H)-Pyrimidinone, 2-(2,2-dimethylpropyl)-6-hydroxy-)
• 7024-58-0(2-Cyclopropylpyrimidine-4,6-diol)